Hermawan, A., & Putri, H. (2022). Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy. Springer.
استشهاد بنمط شيكاغوHermawan, Adam, و Herwandhani Putri. Bioinformatics Analysis Reveals the Potential Target of Rosiglitazone As an Antiangiogenic Agent for Breast Cancer Therapy. Springer, 2022.
MLA استشهادHermawan, Adam, و Herwandhani Putri. Bioinformatics Analysis Reveals the Potential Target of Rosiglitazone As an Antiangiogenic Agent for Breast Cancer Therapy. Springer, 2022.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.